market making clinical team. time encouraged we pipeline milestones programs of by The well was Zevra add the needed therapies commercial Good regulatory quarter We're has Nichol. and advancement and thank Thank you, our dynamic capabilities productive are in-house by us all the to bring morning, and as for progress very to rare for continued towards multiple quite year-to-date directly. joining as disease you near-term been that a for to our today. second
early our which advocacy we of ongoing arimoclomol. In include our support access enhance continue programs patient to efforts, for addition,
you that can innovative advance people resubmission diseases. the slide, An to with rare regarding of towards please? progress NDA we sheet therapy next have believe Our solid we mission the progress the update balance is and our of today much-needed with strategic Nichol, made delivering for to remains arimoclomol. strong, important our
candidate we product treatment Type focused for C with the NPC. a the Disease meeting we the this anticipate or participated review. Our for month, on Niemann-Pick of resubmitting of package a pre-submission that which complete FDA, preview Earlier in
help package and chance The and we will and valuable to complete meeting believe us gain productive the our give that was us collaborative, best we insight success. for
for resubmission strategy remains the targeting Our are we year. end by unchanged, of this resubmission and
and program KPXXXX, intended the for for of treatment narcolepsy. Regarding product the development candidate our IH
Phase end we this trial forward information sharing II And advancing soon that as in with to the quarter. by Our of expected interim IH it's data is as look available.
Based top Phase on be expected of the II XXXX. half line results for the available during pace of first enrollment, are the to trial
In with trial program now Phase enrollments addition, IND in narcolepsy the underway. our initiated has opening I been
second quarter solid a We financial ended the with position.
cash runway cash, $XX.X supports operating million, forecasted our investments into equivalents XXXX, June As cash and XX, of were XXXX. which
important this the year-to-date AZSTARYS $X net a possibility towards addition, of received was the million, the milestone, payment second of which $XX sales net first momentum In milestone milestone quarter XXXX. after AZSTARYS milestone for triggering sales earning sales providing surpassed net sales first million, end was Earning net of program in month. an the
the business, sheet of especially capital continues strength markets. of prevailing given for balance our to source be Our conditions the a
with ongoing highly Directors. both and is step important industry To the our plan. disease in veteran accomplished He is rare round just week, and recent addition, to out Tom events, within welcomed commercial last expertise, another of Anderson a we Board Board refreshment
Board, offering to our been April before advancing to to express initial with Tom shaping company our board XXXX, a our public has Matt want since also retiring our Plooster. mission. and in the our to growth As gratitude we in role Matt and member, we welcome efforts fundamental play his
to want As of I a many to co-founder extend Zevra, my of for personal Matt, you, thanks service. your years
As continues forward, support Board rare the of disease in unified to we Zevra's move be its strategy.
arimoclomol, first ever, our remains with of to the best-in-class disease for has FDA build with commercializing Since a our work an multiple than safety we therapies NDA showcasing the more diseases Now engaged data and package been efficacy in as and optimized company. approach we developing rare arimoclomol. mission the acquiring rare interactions as prepare team patient's
As pre-submission nature received of package. a agency we we collaborative the earlier FDA. the I've by and incorporate the with were important held previously, in mentioned and the meeting that from NDA productive guidance this We meeting, will month, the encouraged we
will expectations As of we by we to that a FDA result, the refined resubmit the end have our full year. the this NDA
XXXX that of June X issues. Orphazyme the from Letter Response Complete FDA the recall, may received you identified main As in
issue, the was The of validation scale the primary as the To instrument to to the disease efficacy use the in related of address first issue plan progression. provide NPCCSS we in this NPC evidence additional and measuring the reliability instrument trial. to used support
removing conduct by analysis X-domain For original a cognition the FDA that NPCCSS is example, of confirmed new it the domain. to acceptable the
the domain. encouraged to swallowing also the to study conduct robustness qualitative assess and of company the validity The a FDA
The with analysis was handle analysis. primary preferred and To analyses. of that be related certain issue to of method events this supportive by second related patient address appropriateness data an the issue, will how affected together additional endpoint FDA the -- primary to was issue we the using second
to strength a is the support the efficacy study. evidence issue third related confirmatory single of to The
new the plan of nonclinical issue, trial. provide additional data clinical well data we studies extension multiple II/III the from address to Phase To the open-label third from as as X-year
the success NPC the arimoclomol parallel NDA ultimately the is we the The constructive with additional believe In resubmission the us for the in regulatory preparation the approved. recent groundwork launch of our FDA U.S. was are that of support we bolster the resubmission, interaction will provided with with of information commercial and laying the benefit for further quality and potential community. of
this making soon as arimoclomol several of There groundbreaking successful strategic a goal the accessible imperatives to are therapy patients as launch. to possible. ensure With
and to payers prescribers. are market We develop with screening, such the arimoclomol We patients the patient working and such benefit genetic development guidelines testing believe early from can tools awareness diagnosis and patient as initiatives, of disease NPC identification through as newborn key finding resources. through other programs,
work for to profile. patients also foundational physicians of a establish engage and treating continuing educating clinical to as NPC We leaders by key its opinion arimoclomol treatment
market best-in-class patient and create diagnosis services patient through to a through caregiver access and to is experience and goal reimbursement Our decrease time the from treatment education, assistance.
experiences. trusted a We advocates are continue And collaboration a patient program support and Zevra and partner tailored with establish NPC we stakeholders including community. key developing access will patient to our as to patient key to the leaders seek within services and close positive approvals, opinion treatment committed insurance
Throughout this journey, people members. families working and medical advocates we inside NPC, caregivers, are to community on with and committed their
NPC. grateful are the who everyone trials We are continues and FDA of treatments for of discussions extremely who supporting meetings for all to development in and those participate
Now let's to attention turn KPXXXX. our
clinical are we Phase rare progressing for is or Beginning trial II nicely. Our with to evaluating IH, sleep development pleased that report KPXXXX disorders. hypersomnia, idiopathic program our
currently are XX sites at We across over enrolling the U.S.
safety expected such potential a are will III to of Phase evaluate Phase inform sleepiness, trial is recall, optimizing may sleep that clinical and KPXXXX trial inertia. randomized-withdrawal data the Interim brain endpoints double-blind, by efficacy of study dose II the used QX placebo-controlled XXXX. to the well you As end as of as fog as be design the the
with reporting patient during for timing the current Potential Phase optimized key and the line through data efficacy differentiators first Based unique need anticipate we II peak pharmacokinetics. pace enrollment, through trial of exposure top sometime include next half year. range expanded of of the alignment dose on
KPXXXX In we trial addition application, in program an April Phase IH, narcolepsy. opening drug the by our investigational II in new IND, in clinical or to ongoing expanded
With thereby sleep KPXXXX the the for goal potential address exploring expanding of indication could adding of that and possibility narcolepsy multiple disorders. the an
initiated I and opening IND is during Phase enrollment The healthy begun. quarter which second has the adults a clinical in was trial study,
As to data narcolepsy in the trial as well Phase as and potential the part initiate forward data with key program. to III IH on evaluate points we the of from as our AZSTARYS seeking in leaning plan programs generated or for IH both narcolepsy, robust program move SDX, by leverage to development we a serdexmethylphenidate
As you is recall, in a SDX may sole pharmaceutical KPXXXX. active ingredient
bringing across both is approach potentially strategic aimed therapy people KPXXXX indications. This enhancing need at life-changing in efficiency in developing to our and this
we development programs. you in regulatory have working been and our progress drive see, can to diligently As
the hand results and will I'll financial on an LaDuane, our provide who to outlook. update over Now call
